Allogeneic CAR-T therapies deliver scalable, off-the-shelf cancer therapy, while autologous CAR-T therapies provide patient-specific but time-intensive treatment.
Shada Warreth
Advertisement
Shada Warreth is Global Partnerships Implementation senior manger at NIBRT and PhD Candidate at TU Dublin, Ireland.
Articles by Shada Warreth
Advertisement
Latest Updated Articles
The Manufacturing Journey of CAR-T Cellular Therapy—An OverviewSeptember 8th 2025
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
3
What 3 Principles Guide Merck's Biologics and ADC Capacity Placement?
4
FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease
5